Dr. David Goldfarb, MD

Dr. Goldfarb graduated from Yale College with a B.A. in biology and received his MD from the Yale School of Medicine. He completed his residency in internal medicine and his fellowship in nephrology at NYU Langone Medical Center and the New York VA Medical Center. He is the Chief of Nephrology at the New York Harbor VA Healthcare System, the Clinical Chief of Nephrology at NYU Langone Medical Center, and Professor of Medicine and Physiology at NYU School of Medicine. He directs kidney stone prevention clinics at NYU and the New York VA. He has been the medical director of the hemodialysis unit at the New York VA since 1994. He was an associate editor of the Clinical Journal of the American Society of Nephrology (CJASN) for five years, and is currently on the editorial board of JASN, CJASN, Kidney International, Urolithiasis and Current Opinion in Nephrology and Hypertension.

He is the former president of the New York Society of Nephrology, was president of the ROCK Society (Research on Calculus Kinetics) for 2015-2016 and serves on the medical advisory board of the National Kidney Foundation Serving Greater New York and the Oxalosis and Hyperoxaluria Foundation. In 2014 he was recognized as the Stone Crusher of the Year by the Oxalosis and Hyperoxaluria Foundation. In 2016 the American Kidney Fund awarded him Nephrologist of the Year. He is the co-editor of 2 books on kidney stones published in 2014. He has also had three calcium oxalate stones.

Dr. Goldfarb is the principal investigator of the cystinuria component of the Rare Kidney Stone Consortium which was funded by the National Institutes of Diabetes, Digestive and Kidney Diseases and the National Center for Advancing Translational Sciences from 2009-2019. He has performed research in many aspects of kidney stones, chronic kidney disease and end stage kidney disease and hemodialysis. He helped plan and execute three VA Cooperative Studies. He has published more than 200 articles which can be viewed here: